Millions of seniors might see higher costs for their prescription drugs following the Trump administration’s decision to end a temporary Medicare subsidy program earlier than expected. Democratic leaders, including New York Governor Kathy Hochul and Senator Kirsten Gillibrand, have voiced their concerns, calling for a reversal of this policy. They argue that this change could impose financial strain on seniors facing rising costs.
Impact of Ending the Subsidy
Medicare Part D covers prescription drugs for millions, primarily benefiting seniors and individuals with disabilities. Introduced in 2024, the Part D Premium Stabilization Demonstration Program aimed to mitigate premium hikes and reduce the effects of Medicare changes under the Inflation Reduction Act. Critics say ending these subsidies will lead to increased costs. The Centers for Medicare & Medicaid Services (CMS) maintains that the program was temporary and that insurers can now accurately price plans without it.
Details on the Decision
Last month, the Trump administration announced plans to conclude the program by December 31, 2026, a year early. Hochul’s office estimates about 1.3 million seniors in New York could be impacted. Gillibrand notes the program’s success in lowering costs, warning of significant premium hikes if it ends. Across the U.S., around 25 million people are part of standalone Medicare Part D plans, though it’s unclear how many will experience higher premiums. Kevin Thompson, CEO of 9i Capital Group, stated that many seniors have benefited from lower costs due to government subsidies compensating for the actual plan costs.
CMS’s Justification
The Trump administration defends the decision, claiming the Part D market has stabilized and subsidies are unnecessary. CMS Administrator Dr. Mehmet Oz claims that most recipients will see a premium increase of less than $10, with some even experiencing reductions. A CMS spokesperson indicated the demonstration program was always meant as a temporary measure to address past market instability, and recent data reflects that plan bids have stabilized.
Next Steps
The subsidy program is set to expire on December 31, 2026. Unless reversed or altered by Congress, beneficiaries must choose 2027 plans without the support that has kept premiums lower since 2024. Alex Beene, a financial literacy instructor, advises beneficiaries to carefully compare plans during Open Enrollment to potentially avoid premium increases. The Medicare landscape appears to be evolving, with drug-price negotiations and out-of-pocket caps offering savings, but careful plan selection is crucial.